RT Journal Article
SR Electronic
T1 Past, Present, and Future of Annexin A5: From Protein Discovery to Clinical Applications*
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 2035
OP 2050
VO 46
IS 12
A1 Hendrikus H. Boersma
A1 Bas L.J.H. Kietselaer
A1 Leo M.L. Stolk
A1 Abdelkader Bennaghmouch
A1 Leonard Hofstra
A1 Jagat Narula
A1 Guido A.K. Heidendal
A1 Chris P.M. Reutelingsperger
YR 2005
UL http://jnm.snmjournals.org/content/46/12/2035.abstract
AB In this article, we review the clinical aspects of imaging with the programmed cell–detecting protein annexin A5 (anxA5). AnxA5 binds to phosphatidylserine, which is one of the “eat me” signals at the surface of the apoptotic cell. This biologic property forms the basis for the development of anxA5 as a diagnostic tool. Within this context, the clinical relevance, limitations, and future perspectives of this approach of visualizing cell death are discussed in this article, as are other potential applications of anxA5. Furthermore, the biologic properties and the radiopharmaceutical, pharmacologic, and biodistribution aspects of anxA5 are reviewed and discussed in this article. Radiolabeled anxA5 bears the promise of becoming a clinically applied radiopharmaceutical with potential applications in cardiology and oncology. Visualization of cell death is important in pathologies such as myocardial infarction, atherosclerosis, and cancer. Furthermore, radiolabeled anxA5 may be developed as a tool for monitoring cell death–inducing or cell death–preventing therapies. In addition, experiences with radiolabeled anxA5 open novel avenues for drug targeting with anxA5 as a biologic “cruise missile.”